1-5 of 5
Peter Hillmen, MBChB, PhD FRCP, FRCPath
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1b-2 Study of KRT-232, a First-in-Class, Oral, Small Molecule Inhibitor of Murine Double Minute 2 (MDM2), in Combination with Acalabrutinib for the Treatment of Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Peter Hillmen, MBChB, PhD FRCP, FRCPath, Hope Qamoos, CNP, Anne Uyei, MD, Wayne M. Rothbaum, Wojciech Jurczak, MD PhD, Catherine Thieblemont, MD PhD, John C. Byrd, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 23–24.
https://doi.org/10.1182/blood-2020-134901
Published: 2020
Journal Articles

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial

Jennifer R. Brown, MD PhD, Tadeusz Robak, MDPhD, Paolo Ghia, MD PhD, Brad S. Kahl, MD, Patricia Walker, MBBS, BMedSci, FRACP, FRCPA, Wojciech Janowski, MBChB, FRCPA, FRACP, Henry Chan, MBChB, FRACP, FRCPA, Mazyar Shadman, MD MPH, Peter S. Ganly, BMBCh, PhD, Luca Laurenti, MD, Stephen Opat, MBBS (Hons), FRACP, FRCPA, Monica Tani, MD, Hanna Ciepluch, MD, Emma Verner, MBBS, BMedSci,FRCPA, FRACP, Martin Šimkovič, MD PhD, Anders Österborg, MD PhD, Marek Trněný, MD, Alessandra Tedeschi, MD, Piers Blombery, MBBS, Jason C. Paik, MD PhD, Fangfang Yin, PhD, Shibao Feng, PhD, Vanitha Ramakrishnan, PhD, Jane Huang, MD, Peter Hillmen, MBChB, PhD FRCP, FRCPath, Constantine S. Tam, MBBS, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–12.
https://doi.org/10.1182/blood-2020-134280
Published: 2020
Journal Articles

Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and del(17p): Arm D of the SEQUOIA (BGB-3111-304) Trial

Constantine S. Tam, MBBS, MD, Ian W. Flinn, MD PhD, Alessandra Tedeschi, MD, Emmanuelle Ferrant, MD, Jennifer R. Brown, MD PhD, Tadeusz Robak, MDPhD, Paolo Ghia, MD PhD, Sowmya B. Kuwahara, PharmD, Jason C. Paik, MD PhD, Lei Hua, PhD, Aileen Cohen, MD PhD, Jane Huang, MD, Peter Hillmen, MBChB, PhD FRCP, FRCPath
Journal: Blood
Blood (2020) 136 (Supplement 1): 24–25.
https://doi.org/10.1182/blood-2020-134179
Published: 2020
Journal Articles

Pooled Analysis of Cardiovascular Events from Clinical Trials Evaluating Acalabrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia (CLL)

Jennifer R Brown, MD PhD, John C. Byrd, MD, Paolo Ghia, MD PhD, Jeff P Sharman, MD, Peter Hillmen, MBChB, PhD FRCP, FRCPath, Deborah M. Stephens, DO, Clare Sun, MD, Wojciech Jurczak, John M. Pagel, MDPhD, Alessandra Ferrajoli, MD, Priti Patel, MD, Marshall Baek, Tamara Lezhava, Nataliya Kuptsova-Clarkson, MD, Javid J. Moslehi, MD, Richard R. Furman, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 52–54.
https://doi.org/10.1182/blood-2020-134797
Published: 2020
Journal Articles

Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)

Arnon P. Kater, MDPhD, Thomas J. Kipps, MD PhD, Barbara Eichhorst, MD, Peter Hillmen, MBChB, PhD FRCP, FRCPath, James D'Rozario, Carolyn Owen, MDFRCPC, Sarit E Assouline, MD MSc, Nicole Lamanna, MD, Tadeusz J. Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, MD PhD, Marco Montillo, Clemens Mellink, Brenda J. Chyla, Cameron Wilson, Jenny Wu, Yanwen Jiang, Marcus Lefebure, Michelle Boyer, John F. Seymour
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–21.
https://doi.org/10.1182/blood-2020-136109
Published: 2020